Key Highlights
- Spear Bio Inc. raises $45 million in Series A financing.
- Co-led by Foresite Capital and Bio-Techne Corporation.
- Innovative SPEAR technology measures protein biomarkers at attomolar levels.
- Funding to expand assay menu and commercial offerings.
Source: Business Wire
Notable Quotes
- “We are grateful for the strong support from such an exceptional group of investors. Foresite has been instrumental in the success of multiple game-changing life science tool and diagnostics companies, and Bio-Techne is a global industry leader, providing solutions for scientific advancements and healthcare breakthroughs.” — Dr. Feng Xuan, Co-founder and CEO at Spear Bio
- “Foresite Capital is excited to support Spear Bio’s transformative mission. I believe SPEAR technology has immense potential to advance neurodegenerative disease research and diagnostics by providing robust and scalable solutions for low-abundant protein biomarker measurement.” — Dr. Vikram Bajaj, Managing Director at Foresite Capital
- “Spear Bio’s ultra-sensitive detection technology offers significant advantages over conventional immunoassay and next-gen proteomic technologies, enabling the quantification of mere dozens of protein molecules in a sample. This level of sensitivity unlocks several challenging applications and high-growth markets, including early diagnosis of neurodegenerative diseases.” — Kim Kelderman, President and CEO at Bio-Techne
SoHC's Take
The recent $45 million Series A financing for Spear Bio Inc. underscores the significant potential of their innovative SPEAR technology in the biotechnology landscape. The ability to measure protein biomarkers at attomolar levels using standard qPCR equipment is a game-changer, particularly for early disease diagnostics and neurodegenerative disease research. This substantial investment by prominent players like Foresite Capital and Bio-Techne highlights the strong confidence in Spear Bio’s vision and technological capabilities. As the company continues to expand its assay menu and commercial offerings, it is poised to make impactful contributions to protein research and healthcare advancements, leveraging the widespread availability of qPCR instruments.
